McKesson Beats Q1 Earnings Estimates, Stock Drops on EPS Decline
McKesson Corporation (MCK), a global healthcare services and IT leader, reported strong adjusted earnings and revenue for Q1 2026. However, shares dropped 5.8% the following day due to a decrease in GAAP EPS.
McKesson's adjusted EPS of $8.26 and revenue of $97.83 billion beat analysts' expectations. Despite this, the stock market fell due to a drop in GAAP EPS. The company operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International.
Analysts rate MCK stock as a 'Strong Buy' with an average price target of $839.27, indicating a potential 6.3% upside. For fiscal 2026, they expect adjusted EPS to grow 15.3% to $38.12. In Q2 2026, analysts forecast adjusted EPS to rise 26.2% to $8.92. The highest target price forecast comes from analyst David Hookstead. MCK stock has climbed 54.9% over the past 52 weeks, outperforming the S&P 500 and the Health Care Select Sector SPDR Fund.
McKesson is set to announce its fiscal Q2 2026 results on Wednesday, Nov. 5, after the market closes. Despite the recent stock market drop, analysts remain bullish on the company's prospects.
